259 related articles for article (PubMed ID: 33958533)
41. Combined intravitreal ranibizumab and zone I sparing laser ablation in infants with posterior zone I retinopathy of prematurity.
Parchand SM; Agrawal D; Gangwe A; Saraogi T; Agrawal D
Indian J Ophthalmol; 2021 Aug; 69(8):2164-2170. PubMed ID: 34304202
[TBL] [Abstract][Full Text] [Related]
42. Preliminary anatomical and neurodevelopmental outcomes of intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity.
Araz-Ersan B; Kir N; Tuncer S; Aydinoglu-Candan O; Yildiz-Inec D; Akdogan B; Ekici B; Demirel A; Ozmen M
Curr Eye Res; 2015 May; 40(6):585-91. PubMed ID: 25025864
[TBL] [Abstract][Full Text] [Related]
43. A Spectrum of Regression Following Intravitreal Bevacizumab in Retinopathy of Prematurity.
Chen TA; Shields RA; Bodnar ZH; Callaway NF; Schachar IH; Moshfeghi DM
Am J Ophthalmol; 2019 Feb; 198():63-69. PubMed ID: 30312578
[TBL] [Abstract][Full Text] [Related]
44. Histological and Immunohistochemical Retinal Changes Following the Intravitreal Injection of Aflibercept, Bevacizumab and Ranibizumab in Newborn Rabbits.
Cam D; Berk AT; Micili SC; Kume T; Ergur BU; Yilmaz O
Curr Eye Res; 2017 Feb; 42(2):315-322. PubMed ID: 27314606
[TBL] [Abstract][Full Text] [Related]
45. A proposal of an algorithm for the diagnosis and treatment of recurrence or treatment failure of retinopathy of prematurity after anti-VEGF therapy based on a large case series.
Martínez-Castellanos MA; González-H León A; Romo-Aguas JC; Gonzalez-Gonzalez LA
Graefes Arch Clin Exp Ophthalmol; 2020 Apr; 258(4):767-772. PubMed ID: 31953595
[TBL] [Abstract][Full Text] [Related]
46. Efficacy and safety of intravitreal bevacizumab for the treatment of retinopathy of prematurity: a single-center retrospective review.
Frosini S; Franco F; Vicini G; Nicolosi C; Varriale G; Dani C; Virgili G; Giansanti F
J Matern Fetal Neonatal Med; 2022 Sep; 35(17):3337-3342. PubMed ID: 32933350
[TBL] [Abstract][Full Text] [Related]
47. Characteristics of retinal vascularization in reactivated retinopathy of prematurity requiring treatment and clinical outcome after reinjection of ranibizumab.
Jang JH
Sci Rep; 2024 Jul; 14(1):15647. PubMed ID: 38977744
[TBL] [Abstract][Full Text] [Related]
48. Intravitreal injection of bevacizumab for retinopathy of prematurity.
Kuniyoshi K; Sugioka K; Sakuramoto H; Kusaka S; Wada N; Shimomura Y
Jpn J Ophthalmol; 2014 May; 58(3):237-43. PubMed ID: 24566819
[TBL] [Abstract][Full Text] [Related]
49. Effects of Intravitreal Ranibizumab in the Treatment of Retinopathy of Prematurity in Chinese Infants.
Yi Z; Su Y; Zhou Y; Zheng H; Ye M; Xu Y; Chen C
Curr Eye Res; 2016 Aug; 41(8):1092-1097. PubMed ID: 26580816
[TBL] [Abstract][Full Text] [Related]
50. Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity.
Huang CY; Lien R; Wang NK; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC; Wu WC
Graefes Arch Clin Exp Ophthalmol; 2018 Mar; 256(3):479-487. PubMed ID: 29290015
[TBL] [Abstract][Full Text] [Related]
51. Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity.
Erol MK; Coban DT; Sari ES; Bilgin AB; Dogan B; Ozdemir O; Tunay ZO
Arq Bras Oftalmol; 2015; 78(6):340-3. PubMed ID: 26677033
[TBL] [Abstract][Full Text] [Related]
52. Development of refractive error in children treated for retinopathy of prematurity with anti-vascular endothelial growth factor (anti-VEGF) agents: A meta-analysis and systematic review.
Tan QQ; Christiansen SP; Wang J
PLoS One; 2019; 14(12):e0225643. PubMed ID: 31790445
[TBL] [Abstract][Full Text] [Related]
53. Clinical outcome following reinjection of Ranibizumab for reactivation of retinopathy of prematurity.
Bassiouny RM; Gaafar WM; El Nokrashy A; Abdelhameed AG; Attallah EA; Elgharieb AG; Bassiouny MR
Eye (Lond); 2022 Nov; 36(11):2137-2143. PubMed ID: 34711941
[TBL] [Abstract][Full Text] [Related]
54. Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity.
Karkhaneh R; Khodabande A; Riazi-Eafahani M; Roohipoor R; Ghassemi F; Imani M; Dastjani Farahani A; Ebrahimi Adib N; Torabi H
Acta Ophthalmol; 2016 Sep; 94(6):e417-20. PubMed ID: 27009449
[TBL] [Abstract][Full Text] [Related]
55. SAFER-ROP: Updated Protocol for Anti-VEGF Injections for Retinopathy of Prematurity.
Beck KD; Rahman EZ; Ells A; Mireskandari K; Berrocal AM; Harper CA
Ophthalmic Surg Lasers Imaging Retina; 2020 Jul; 51(7):402-406. PubMed ID: 32706898
[TBL] [Abstract][Full Text] [Related]
56. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial.
Geloneck MM; Chuang AZ; Clark WL; Hunt MG; Norman AA; Packwood EA; Tawansy KA; Mintz-Hittner HA;
JAMA Ophthalmol; 2014 Nov; 132(11):1327-33. PubMed ID: 25103848
[TBL] [Abstract][Full Text] [Related]
57. Refractive error outcomes after intravitreal ranibizumab for retinopathy of prematurity.
Meng Q; Cheng Y; Wu X; Zhao D; Zhao M; Liang J
Clin Exp Optom; 2020 Jul; 103(4):495-500. PubMed ID: 31802528
[TBL] [Abstract][Full Text] [Related]
58. Intravitreal bevacizumab injection in aggressive posterior retinopathy of prematurity compared with type I retinopathy of prematurity.
Eftekhari Milani A; Hassanpoor N; Mousavi Mirkala M; Taheri A; Golizade A; Niyousha MR
Int Ophthalmol; 2020 Feb; 40(2):477-482. PubMed ID: 31712928
[TBL] [Abstract][Full Text] [Related]
59. Refractive outcomes comparing primary laser to primary bevacizumab with delayed laser for type 1 ROP.
Anand N; Blair MP; Greenwald MJ; Rodriguez SH
J AAPOS; 2019 Apr; 23(2):88.e1-88.e6. PubMed ID: 30797978
[TBL] [Abstract][Full Text] [Related]
60. Treatment of type I ROP with intravitreal bevacizumab or laser photocoagulation according to retinal zone.
Mueller B; Salchow DJ; Waffenschmidt E; Joussen AM; Schmalisch G; Czernik C; Bührer C; Schunk KU; Girschick HJ; Winterhalter S
Br J Ophthalmol; 2017 Mar; 101(3):365-370. PubMed ID: 27301450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
